Related Experiment Video

Updated: Aug 11, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Once-daily fluticasone propionate in stable asthma: study on airway inflammation

Albert M Li1, Tony W T Tsang, Karen Chan

  • 1Department of Pediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. albertmli@cuhk.edu.hk

The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|March 7, 2006
PubMed

Insights

Switching children with stable asthma from twice-daily to once-daily fluticasone propionate (FP) significantly reduced airway inflammation markers. This change in dosing frequency was also preferred by the children, indicating improved adherence and asthma management.

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Asthma is a chronic respiratory disease affecting children.
  • Inhaled corticosteroids (ICS) are a cornerstone of asthma management.
  • Fluticasone propionate (FP) is a commonly prescribed ICS.

Purpose of the Study:

  • To evaluate the efficacy of once-daily FP dosing in children with stable asthma.
  • To assess the impact of reduced dosing frequency on inflammatory markers.
  • To determine children's preference for once-daily versus twice-daily FP administration.

Main Methods:

  • A study involving 29 children with stable asthma (mean age 10.6 years).
  • Measurements included spirometry, exhaled nitric oxide (eNO), and sputum eosinophils at baseline and after 8 weeks.
  • Fluticasone propionate (FP) dosage was changed from twice-daily to once-daily, maintaining the total dose.

Main Results:

  • Significant reduction in exhaled nitric oxide (eNO) levels (p = 0.037).
  • Significant decrease in sputum eosinophil counts (p = 0.024).
  • All participants preferred the once-daily dosing regimen.

Conclusions:

  • Once-daily fluticasone propionate (FP) is effective in controlling airway inflammation in children with stable asthma.
  • Reducing dosing frequency to once-daily improves adherence and is preferred by pediatric patients.
  • This regimen offers a viable alternative for pediatric asthma management.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...